Physician profile
Komal Narula
NPI 1184724890
$3,609.39
in general payments reported to CMS, 2019-2025
35 companies · $621 in 2025
The $621 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.55 · 2020: $202 · 2021: $673 · 2022: $815 · 2023: $731 · 2024: $488 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $988.46 | 2019-2025 | |
| Astellas Pharma US INC | $344.95 | 2022-2025 | Veozah |
| Mayne Pharma Commercial LLC | $293.31 | 2021-2025 | |
| Aspira Women'S Health INC | $264.00 | 2021-2024 | Ova1 |
| Agile Therapeutics, INC. | $158.88 | 2021-2024 | Twirla |
| Hologic Sales and Service, LLC | $147.62 | 2022-2025 | Myosure Tissue Removal Device, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Coolseal Generator |
| Exeltis, USA INC. | $131.62 | 2021-2024 | Slynd |
| Sumitomo Pharma America, INC. | $129.78 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $119.69 | 2021-2024 | Injectafer |
| Evofem Biosciences, INC. | $104.07 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $103.89 | 2023-2025 | Exparel, Zilretta, Iovera |
| Myovant Sciences INC. | $91.09 | 2021-2022 | |
| Therapeuticsmd, INC. | $82.01 | 2020-2022 | |
| Organon LLC | $69.17 | 2023-2024 | Nexplanon |
| Mylan Pharmaceuticals INC. | $62.01 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $55.75 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $50.61 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.11 | 2019-2023 | |
| Coopersurgical, INC. | $44.26 | 2024 | Paragard T 380a |
| Amgen INC. | $38.18 | 2024-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $35.12 | 2024-2025 | |
| Minerva Surgical, INC | $32.05 | 2021-2022 | |
| Allergan, INC. | $26.27 | 2020 | |
| Novo Nordisk INC | $22.65 | 2025 | Wegovy |
| Gynesonics, INC. | $19.26 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Biohaven Pharmaceutical Holding Company LTD. | $17.55 | 2022 | |
| Merck Sharp & Dohme LLC | $17.25 | 2024 | Gardasil 9, Gardasil |
| Novum Pharma, LLC | $16.37 | 2019 | |
| Coloplast Corp | $15.94 | 2021 | |
| Currax Pharmaceuticals LLC | $14.91 | 2024 | Contrave |
| Alexion Pharmaceuticals, INC. | $14.36 | 2025 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $12.74 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.37 | 2019 | |
| Lupin INC. | $11.92 | 2021 | |
| Avion Pharmaceuticals | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Komal Narula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.